Heart Failure

A discussion on the differences of sacubitril-valsartan and spironolactone for the treatment of heart failure.

A discussion on the promising findings from the TOPCAT study.

An expert in the management of heart failure considers the importance of recent findings from the PARALLAX study.

New study findings may pave the way for research into the prognostic value of white matter lesions in heart failure and the impact that HF therapies have on them.

Amid speculation that total blood counts may be associated with heart failure prognosis, researchers find that higher levels of platelet distribution width could be used to predict a worse prognosis for heart failure.

Patients with heart failure should be prioritized during vaccine rollout because of increased mortality risks reportedly associated with coronavirus disease 2019 (COVID-19).

An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile.

An expert physician provides an overview of the PROVE-HF trial and considers the practical implications for heart failure with reduced ejection fraction.

A discussion on how the economic burden of management differs for patients with HFpEF and HFrEF.

A key opinion leader considers how to ensure patients with HFpEF and HFrEF receive therapy in a timely and appropriate manner.

Recent study findings highlight mixed results following use of this medication among Mississippi and Massachusetts Medicaid beneficiaries.

Our top heart failure articles of the year cover a groundbreaking development for dapagliflozin, address the important issue of disparities in this space, and see coronavirus disease 2019 make yet another appearance.

Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF.

Key opinion leaders enumerate the challenges of treating patients with HFpEF.

Hoping to improve outcomes among patients with acute heart failure discharged from the emergency department, study findings show that 30-day improvements from a self-care intervention were not sustainable through 90 days.

This week, the top managed care news included the first coronavirus disease 2019 vaccine shipments arriving nationwide; FDA panel votes to expand use of heart failure drug; efforts to address social determinants of health amid the pandemic.

A 5-phase program designed to increase knowledge among patients with heart failure has shown promise in more effective disease management and hospital readmission reduction.

The panel could not reach consensus on what an expanded label might look like in an area where there are no approved therapies.

A discussion on utilization management strategies for optimizing the treatment for patients with heart failure.

Key opinion leaders provide an overview of the treatment gaps in the management of heart failure.

Due to a lack of comprehensive data on health literacy among these patients, a team of investigators looked at its connection with their quality of life (QOL).

Top reasons why patients with heart failure face a higher risk of hospitalization during times when fracking occurs include an increase in air pollution and stress pathways.

An expert in the management of heart failure discusses the standard of care for patients with reduced ejection fraction.

Expert physicians consider the treatment goals for patients with heart failure.

Overdose-related cardiac arrests rose consistently in the first few months of the coronavirus disease 2019 (COVID-19) pandemic, coming in at 48.5% above baseline through August 1, according to national emergency medical services data.